Evidence mapPaperPMID 40383639Full record

ArticleEndocrine journal2025

Sarcopenia in children with acute leukemia worsened after induction therapy.

Tomoyo Itonaga, Fumika Matsuda, Naoki Hirano, Miwako Maeda, Souichi Suenobu, Kenji Ihara

Abstract read
In one paragraph

Article in Endocrine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomoyo ItonagaDepartment of Pediatrics, Oita University Faculty of Medicine, Oita 879-5593, Japan.ORCID http://orcid.org/0000-0003-4894-5356
Fumika MatsudaDepartment of Pediatrics, Oita University Faculty of Medicine, Oita 879-5593, Japan.
Naoki HiranoDepartment of Pediatrics, Oita University Faculty of Medicine, Oita 879-5593, Japan.ORCID http://orcid.org/0000-0002-9695-7004
Miwako MaedaDepartment of Pediatrics, Oita University Faculty of Medicine, Oita 879-5593, Japan.
Souichi SuenobuDepartment of Pediatrics, Oita University Faculty of Medicine, Oita 879-5593, Japan.ORCID http://orcid.org/0000-0002-6266-1088
Kenji IharaDepartment of Pediatrics, Oita University Faculty of Medicine, Oita 879-5593, Japan.ORCID http://orcid.org/0000-0002-8831-1991

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenia is a prevalent condition among elderly individuals and is characterized by the loss of skeletal muscle mass accompanied by physical dysfunction. In older adults, decreased insulin-like growth factor 1 (IGF-1) has been implicated as a contributing factor to the development of sarcopenia. Children with chronic conditions associated with sarcopenia are rarely evaluated. This study aimed to evaluate muscle mass using cross-sectional computed tomography (CT) images in pediatric patients with acute leukemia and patients without chronic diseases, and to examine the relationship between skeletal muscle mass volume and various growth parameters in children with acute leukemia. The study included 44 pediatric patients (age: 1-15 years) with newly diagnosed acute leukemia (B-cell lymphoblastic leukemia, n = 30; T-cell lymphoblastic leukemia, n = 5; other types, n = 9) who underwent abdominal CT before treatment initiation. Among these, 15 underwent abdominal CT after induction therapy. The total psoas muscle area at lumbar vertebrae levels 3-4, body height, weight, and IGF-1 levels were retrospectively analyzed. The total psoas muscle area significantly decreased after induction therapy in all 15 patients. A significant correlation was observed between the rate of change in total psoas muscle area and IGF-1 levels (n = 9; p < 0.05; r = -0.84). However, no correlation was identified between the rate of change in total psoas muscle area and height velocity before and after treatment. In conclusion, skeletal muscle mass decreased following treatment initiation in pediatric patients with acute leukemia. The degree of muscle mass loss was more severe in patients with higher pre-treatment IGF-1 levels.

Indexed as

Induction ChemotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaSarcopeniaAdolescentChildChild, PreschoolCross-Sectional StudiesFemaleHumansInfantInsulin-Like Growth Factor IMaleMuscle, SkeletalPsoas MusclesRetrospective StudiesTomography, X-Ray ComputedIGF1 protein, humanInsulin-Like Growth Factor IAcute leukemiaHeight velocityInsulin-like growth factor 1 (IGF-1)Psoas muscle areaSarcopenia

Identifiers

PMID40383639
PMCPMC12436073

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.